Methamphetamine and amphetamine are closely related stimulants that share a core chemical structure, but methamphetamine has an extra methyl group attached to its nitrogen atom. That small structural tweak makes a large practical difference: methamphetamine crosses into the brain faster, releases more dopamine per dose, and carries substantially greater risks of neurotoxicity and addiction. Both substances increase alertness, suppress appetite, and elevate heart rate, yet they sit in very different places in medicine and law, and lumping them together obscures important distinctions in how they affect the body.
The Chemical Difference and Why It Matters
Amphetamine is the simpler molecule. Methamphetamine is amphetamine with one additional methyl group (a carbon atom bonded to three hydrogens) on the amine portion of the molecule. That extra piece of chemical architecture makes methamphetamine more fat-soluble, which means it slips across the blood-brain barrier more readily. Once inside the brain, the two drugs target the same systems but with different intensity.
Both drugs force monoamine transporters to work in reverse, pumping dopamine, norepinephrine, and serotonin out of nerve terminals into the space between neurons. Amphetamines as a class bind to the norepinephrine transporter with considerably higher affinity than to the dopamine transporter, which is why they boost norepinephrine release more potently than dopamine release overall.1Frontiers in Neuroanatomy. The Effects of Amphetamine and Methamphetamine on the Release of Norepinephrine, Dopamine and Acetylcholine From the Brainstem Reticular Formation But methamphetamine is especially aggressive at the dopamine transporter. At the same concentration and voltage, methamphetamine released roughly five times more dopamine than amphetamine in laboratory experiments, and it also released about twice as much calcium from internal stores. In living rats, methamphetamine blocked dopamine clearance more efficiently than amphetamine did, leaving more dopamine floating around in the reward-related nucleus accumbens.2PubMed Central. Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo That flood of dopamine is a big part of why methamphetamine produces a more intense high and a steeper path toward compulsive use.
How the Body Handles Each Drug
The pharmacokinetics of the two drugs diverge in ways that reinforce the potency gap. In mouse studies, the area under the concentration-time curve for methamphetamine in both blood and brain was roughly seven to ten times that of amphetamine, meaning the body is exposed to much higher cumulative drug levels after a dose of methamphetamine.3PubMed Central. A combined study of pharmacodynamics and pharmacokinetics of methamphetamine and its metabolite in male mice The body actually converts a portion of methamphetamine into amphetamine as it metabolizes the drug, so a methamphetamine user effectively gets hit with both substances.
Route of administration amplifies these differences on the street. Methamphetamine is commonly smoked or snorted. Intranasal bioavailability sits around 79%, while smoking delivers roughly 67% of the estimated dose that reaches the pipe.4PubMed. The bioavailability of intranasal and smoked methamphetamine These efficient routes get large amounts of drug into the bloodstream quickly, which intensifies the rush and strengthens the reinforcing cycle that drives addiction. Prescription amphetamines, by contrast, are almost always taken orally, which produces a slower, steadier rise in blood levels.
Medical Uses
Amphetamine is one of the most commonly prescribed stimulants in the world. Mixed amphetamine salts and dextroamphetamine are first-line treatments for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. At therapeutic oral doses, amphetamine improves focus and wakefulness without producing the extreme dopamine surge associated with illicit use. Its cognitive effects at low-to-moderate doses follow an inverted-U pattern: a moderate dose sharpens brain activity patterns associated with working memory, while a high dose disrupts those same patterns and impairs performance.5PubMed Central. Amphetamine Exerts Dose-Dependent Changes in Prefrontal Cortex Attractor Dynamics during Working Memory Systematic reviews show that in healthy individuals without ADHD, amphetamine’s cognitive benefits are inconsistent and do not reliably improve working memory, though it may sharpen attention and processing speed.6PubMed Central. Systematic reviews of the acute effects of amphetamine on working memory and other cognitive performances in healthy individuals, with a focus on the potential influence of personality traits
Methamphetamine also has a legal medical form. Desoxyn, a brand-name prescription methamphetamine, is approved in the United States for ADHD and short-term obesity treatment, though it is rarely prescribed. Doctors overwhelmingly choose amphetamine-based medications instead. The medical existence of methamphetamine is a point of confusion for many people, but the controlled low doses in a pill form bear little resemblance to the high-dose smoked or injected use seen in addiction.
Neurotoxicity
This is where the two drugs diverge most dramatically. While high or repeated doses of amphetamine can harm nerve terminals, methamphetamine causes notably more persistent damage. In animal studies, methamphetamine preferentially reduced dopamine transporter levels in the striatum, while amphetamine’s damage profile differed in its regional pattern and degree.7PubMed Central. Methamphetamine-, d-Amphetamine-, and p-Chloroamphetamine-Induced Neurotoxicity Differentially Effect Impulsive Responding on the Stop-Signal Task in Rats Methamphetamine produces lasting damage to both dopamine and serotonin nerve terminals through a cascade of oxidative stress, mitochondrial dysfunction, and excitotoxicity.8PubMed Central. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine
In people with a history of chronic methamphetamine use, neuroimaging studies reveal structural and functional brain changes that are not typically seen with prescribed amphetamine. These include reduced gray matter in the cingulate and limbic cortex (averaging about 11% below healthy controls), smaller hippocampal volumes (about 8% smaller), and unusual white-matter expansion.9Journal of Neuroscience. Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine Those hippocampal deficits correlated with poorer performance on word-recall memory tests. Beyond structural shrinkage, chronic methamphetamine users show signs of neuroinflammation, disrupted brain connectivity, and deficits in self-control and decision-making that can persist well into recovery.10PubMed Central. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging
Amphetamine at therapeutic doses does not produce comparable structural damage. The contrast is partly about dose, partly about route of delivery, and partly about the inherent pharmacological differences described earlier. A person taking a prescribed oral amphetamine tablet for ADHD is in a fundamentally different situation from someone smoking large amounts of methamphetamine repeatedly.
Cardiovascular Risks
Both stimulants raise blood pressure and heart rate, but methamphetamine’s cardiovascular toll is in a different league. After overdose and accidents, cardiovascular disease is the leading cause of death among methamphetamine users. The damage includes vasoconstriction, accelerated plaque buildup in arteries, cardiac arrhythmias, and cardiomyopathy (weakening of the heart muscle).11PubMed Central. Methamphetamine Use and Cardiovascular Disease
Research comparing methamphetamine users who developed heart or lung disease with users whose hearts remained structurally normal found that the mortality rate over a median follow-up of about 20 months was roughly 18% for those who developed pulmonary arterial hypertension and about 15% for those with cardiomyopathy, compared with under 5% for users whose hearts appeared normal. Male sex, existing high blood pressure, and alcoholism were strongly associated with developing the cardiomyopathy pattern, while women were disproportionately represented among those who developed pulmonary arterial hypertension.12PubMed. Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary Arterial Hypertension and Dilated Cardiomyopathy These findings underscore that chronic methamphetamine use creates a cardiac risk profile that prescribed amphetamine does not typically produce.
Psychosis and Mental Health
High-dose stimulant use of either type can trigger psychotic symptoms, including paranoia and hallucinations. But methamphetamine psychosis has been studied extensively and is recognized as a distinct clinical phenomenon. The paranoid-hallucinatory states it produces can be indistinguishable from paranoid schizophrenia and may persist long after the drug’s direct pharmacological effects have cleared. People who have experienced methamphetamine-associated psychosis are also vulnerable to spontaneous recurrences triggered by stress, even without taking the drug again.13PubMed Central. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia This “sensitization” effect, where the brain becomes primed to re-enter a psychotic state, is one of the more alarming long-term consequences specific to heavy methamphetamine use.
Drug Testing Complications
Standard urine drug screens group both drugs under the “amphetamines” class, which creates real-world confusion. Because the body converts methamphetamine into amphetamine, someone who uses methamphetamine will test positive for both. But the reverse also happens in a much subtler way: a person taking only prescribed amphetamine can produce trace amounts of methamphetamine in their urine. A recent analysis of urine samples found that in about 69% of cases where methamphetamine was detected alongside amphetamine, the methamphetamine level was less than 2% of the amphetamine concentration, suggesting the person had taken amphetamine rather than methamphetamine. This trace methamphetamine appears to come from a minor metabolic pathway in which the body adds a methyl group to amphetamine.14PubMed Central. Origin and Interpretation of Low Methamphetamine Levels Found in Amphetamine‐Positive Urine Samples: Support for Methylation of Amphetamine as a Minor Metabolic Pathway
A separate complication arises with certain older weight-loss medications. When benzphetamine (a now-uncommon diet drug) is metabolized, it produces both amphetamine and methamphetamine as metabolites. The ratio of the two can look quite different from what you would see in someone who used methamphetamine directly.15PubMed. Detection of amphetamine and methamphetamine following administration of benzphetamine This is one reason forensic toxicologists use chiral analysis, a technique that can distinguish between the left-handed and right-handed mirror-image forms of these molecules, to determine whether a positive test result came from illicit methamphetamine, a prescribed amphetamine medication, or another drug entirely.
Prenatal Exposure
The effects of prenatal methamphetamine exposure are a growing area of concern. In a study following children from birth to age three, those exposed to methamphetamine in the womb scored about 3 points lower on gross motor development compared with unexposed children. Fine motor scores were not significantly affected overall, though boys scored lower than girls on fine motor tasks regardless of exposure status. Heavy methamphetamine exposure did not produce additional measurable deficits on the developmental scales used, and birth weight did not mediate the observed effects.16PubMed Central. Prenatal methamphetamine exposure and neurodevelopmental outcomes in children from 1 to 3 years The findings are concerning but more subtle than many people assume. Research on prenatal amphetamine exposure at prescribed therapeutic doses (for ADHD, for example) is far more limited, and the two situations should not be conflated.
A Brief History of Both Drugs
Amphetamine was first synthesized in the late 1800s and entered clinical use in the 1930s, initially as a nasal decongestant. Methamphetamine was synthesized in Germany in 1937 and commercially released the following year. It quickly became popular as a fatigue fighter for night-shift workers and a party drug for young people, until Germany restricted it in mid-1941. During World War II, commanding officers distributed methamphetamine tablets to troops to combat exhaustion, sometimes over objections from military physicians.17PubMed. Methamphetamine for Hitler’s Germany: 1937 to 1945 Similar wartime stimulant use occurred on the Allied side, primarily with amphetamine. After the war, both drugs saw widespread civilian use before tighter regulations were introduced in the 1960s and 1970s.
Today, most forms of amphetamine are classified as Schedule II controlled substances in the United States, meaning they have recognized medical uses but high abuse potential. Methamphetamine is also Schedule II due to its rare medical application (Desoxyn), but illicit methamphetamine manufacturing and trafficking are among the most serious drug enforcement challenges worldwide.
Illicit Manufacturing and Purity
Street methamphetamine and street amphetamine often contain chemical byproducts that reveal how they were made. Forensic chemists use impurity profiling to trace synthesis routes. For example, the detection of phenyl-2-propanone (P2P) and specific organic impurities in amphetamine samples pointed to a particular synthesis pathway called the Leuckart reaction. Methamphetamine samples also contained P2P, meaning multiple synthesis routes could not be ruled out.18Sains Malaysiana. Impurity Profiling of Amphetamine and Methamphetamine Using Gas Chromatography Mass Spectrometry (GCMS) Harmonised Methods For the user, the practical takeaway is that illicit versions of both drugs frequently contain unpredictable contaminants. The purity, composition, and even the ratio of left-handed to right-handed molecules can vary wildly between batches, adding another layer of risk on top of the drugs’ inherent dangers.
Treatment for Methamphetamine Use Disorder
One of the starkest practical differences between the two drugs is in addiction treatment. Amphetamine-based medications are sometimes proposed as replacement therapy for methamphetamine addiction, similar to how methadone or buprenorphine replace heroin. However, current evidence suggests that amphetamines used as a replacement pharmacotherapy for methamphetamine use disorder do not show benefit. Methylphenidate (a different stimulant, best known as Ritalin) has shown a more positive signal, especially in methamphetamine users who also have underlying ADHD, though much larger studies are needed before it could become a standard treatment.19Psychopharmacology Institute. Experimental Pharmacotherapies for Stimulant Use Disorder No medication is currently approved specifically for methamphetamine addiction, which makes behavioral therapies the primary approach. This is a notable gap compared with opioid and alcohol use disorders, where multiple effective medications exist.
For people dealing with amphetamine dependence from misuse of prescription drugs, the situation is different. Tapering the dose under medical supervision, along with therapy, is a more straightforward process because the starting point is a pharmaceutical-grade substance at known doses. Methamphetamine addiction tends to involve higher doses, more neurotoxic exposure, and a more entrenched pattern of compulsive use, all of which make recovery harder and longer.